Pfizer Agrees to $44 Million Settlement in Chantix Lawsuit

Pharmaceutical giant Pfizer has agreed to a $44 million class action settlement concerning its smoking cessation drug, Chantix. The settlement addresses claims that the oral prescription medication, which was initially approved by the U.S. Food and Drug Administration (FDA) in May 2006 and later removed from the market in 2021, was contaminated with high levels of nitrosamine. Nitrosamine is identified as a known carcinogen that can increase the risk of developing cancer. The lawsuit further alleged that Pfizer failed to adhere to current good manufacturing practices, engaged in negligence, and violated consumer protection laws. Pfizer has maintained its innocence throughout the legal proceedings, stating in the settlement agreement that the company "believes it did nothing wrong and denies that it violated any law." The decision to settle was made to mitigate the "uncertainties and expenses" associated with continued litigation.

Eligibility for payouts extends to any individual or third party in the United States and its territories who purchased Chantix between September 29, 2015, and September 17, 2021. To qualify for compensation, consumers must provide documentation verifying their purchases, such as receipts or credit card statements. Payments will be distributed on a "pro rata basis," meaning the amount received will be proportional to the funds spent on the drug, with a maximum reimbursement capped at 20% of the total Available Settlement Fund. Crucially, individual claims cannot exceed the actual amount a consumer spent on the medication. Any remaining funds after consumer claims are processed will be allocated to third-party payors. The final determination of consumer payouts is contingent upon the approval hearing scheduled for October 13, 2026.

Individuals seeking to file a claim are directed to the official settlement website. The settlement instructions advise claimants to complete a claim form either online or by downloading a paper version for mailing. The inclusion of supporting documentation is encouraged to strengthen claims. The deadline for submitting claim forms online is September 14, 2026. For those opting to mail their forms, they must be postmarked by the same date. The settlement aims to provide compensation to eligible consumers who purchased Chantix during the specified period, addressing concerns over product safety and manufacturing standards. The drug's removal from the market in 2021 followed reports of nitrosamine contamination, prompting regulatory scrutiny and subsequent legal action. The class action lawsuit consolidated numerous claims from individuals who alleged harm or potential harm due to the drug's composition and Pfizer's manufacturing practices.